We are honored to have Tom Hassenboehler, Chief Counsel to the Energy and Power Subcommittee, U.S. House of Representatives Energy & Commerce Committee, join us to provide his thoughts and outlook on where the industry is headed in 2014. Mr. Hassenboehler manages some of the committee’s most pressing issues, including the Keystone XL pipeline and the Environmental Protection Agency’s greenhouse-gas regulations.
Topics
- Who is going to pay for grid security?
- Tax extender proposal and Senate Finance Committee markup – what impact will it have on renewable energy?
- Has energy storage found a place in the Beltway’s view of U.S. generation?
- Will the EPA allow new coal plants to be built?
- The federal government’s role in energy efficiency.
- Keystone XL and its prospects.
- Should the United States export gas/oil?
- Future of nuclear power, including waste storage.
Speakers
- Tom Hassenboehler, Chief Counsel, Energy and Power Subcommittee, U.S. House of Representatives Energy & Commerce Committee
- Jason W. Allen, Partner, Foley & Lardner LLP
- Bradley D. Jackson, Partner, Foley & Lardner LLP
- Scott Klug, Director of Public Affairs, Foley & Lardner LLP
RSVP
There is no cost to participate in this program, but pre-registration is required.
For additional information, please contact Zulaikha Rahim at [email protected].
People
Related Insights
09 May 2024
Events
The FTC Noncompete Rule: Where Do We Go From Here?
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Article
FTC Finalizes Rule Against Employee Noncompetes
On April 23, 2024, the Federal Trade Commission voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Health Care Law Today
FDA Continues to Take Stance That it Will Not Issue CBD Rules
The FDA recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of CBD and a new regulatory pathway is needed.